Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Konstantinos Gkodopoulos"'
Autor:
Maria K. Angelopoulou, Maria Stamouli, Eirini Grigoriou, Mark W. Lowdell, Maria Tsirogianni, Georgia Stavroulaki, Kleopatra Dagla, Konstantinos Gkirkas, Violetta Kapsimalli, Eve Konsta, Konstantinos Gkodopoulos, Vassiliki Pappa, Panagiotis Tsirigotis, Angeliki Karagiannidou
Publikováno v:
Leukemialymphoma. 60(10)
The aim of the present study was to identify biomarkers predictive of the outcome of patients with high-risk myelodysplastic syndrome and oligoblastic acute myeloid leukemia (AML) treated with 5-azacytidine (AZA). We prospectively examined the associ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ca4987de08a7379468c6da314dba653
https://pubmed.ncbi.nlm.nih.gov/31120354
https://pubmed.ncbi.nlm.nih.gov/31120354
Autor:
Loukas Kaklamanis, Konstantinos Gkodopoulos, Angeliki Karagiannidou, Konstantinos Gkirkas, Aiantas Antoniades, Maria Stamouli, George Makavos, Ignatios Ikonomidis, Panagiotis Tsirigotis, John Palios
Publikováno v:
Annals of Hematology. 98:1775-1776
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b677641ab088bcc806b72c1d2cb068c3
https://doi.org/10.1007/s00277-019-03665-3
https://doi.org/10.1007/s00277-019-03665-3
Autor:
Georgia Stavroulaki, Anthi Bouhla, Vassiliki E. Mpakou, Argiris Symeonidis, Thomas P. Thomopoulos, Vassiliki Pappa, George Dimitriadis, Frieda Kontsioti, Sotirios G. Papageorgiou, Konstantinos Gkodopoulos, Eirini Glezou, Efthimia Bazani, Eirini Maratou
Publikováno v:
Blood. 134:5176-5176
INTRODUCTION AML is the most common malignant myeloid disorder in adults. Relapses are initiated by chemoresistant leukemic cells. DNA damage and repair mechanisms influence not only the genetic predisposition to leukemia but are also very important
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::beb17e07743b2cc357eb8de6164eb844
https://doi.org/10.1182/blood-2019-127501
https://doi.org/10.1182/blood-2019-127501
Autor:
Vassiliki Pappa, Zoi Tsakiraki, Aris Spathis, Frieda Kontsioti, Athanasios Galanopoulos, Periklis G. Foukas, Vassiliki E. Mpakou, Efthimia Mpazani, Nora-Athina Viniou, Argiris Symeonidis, Ioannis Kotsianidis, Anthi Bouhla, Kalliopi Zafeiropoulou, Georgia Stavroulaki, Sotirios G. Papageorgiou, Irene Glezou, Konstantinos Gkodopoulos
Publikováno v:
Blood. 134:5403-5403
Introduction: Azacitidine (AZA) is a hypomethylating agent that at low doses acts by inhibiting DNA methyltranferase activity. AZA is approved and widely used for the treatment of MDS patients and patients with AML not candidate for intensive chemoth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2252dfe56ee0f0d2fba87378ab79c2eb
https://doi.org/10.1182/blood-2019-122424
https://doi.org/10.1182/blood-2019-122424